Associated Papers
Pharmacogenetic influence on bupropion bioactivation and clinical outcomes in major depressive disorder.
Kharasch ED et al.
The Journal of Pharmacology and Experimental Therapeutics, 2026
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Sub- and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study.
Soeria-Atmadja S et al.
British Journal of Clinical Pharmacology, 2025
Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid.
Taylor J et al.
Southern African Journal of Hiv Medicine, 2025
Pharmacogenetics in Tuberculosis-HIV Coinfected Populations: A Systematic Review of Genetic Variants Influencing Antiretroviral and Anti-Tuberculosis Drug Response.
Hardi H et al.
Journal of Multidisciplinary Healthcare, 2025
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer: A Secondary Analysis of the PREPARE Randomized Clinical Trial.
Roncato R et al.
Jama Network Open, 2024
CYP2B6 and ABCB1 genotypes predict methadone plasma exposure among patients on maintenance therapy against opioid addictions in Tanzania.
Mugusi S et al.
British Journal of Clinical Pharmacology, 2024
Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype.
Eniayewu O et al.
Pharmacogenetics and Genomics, 2024
Mapping the Pharmacogenetic Landscape in a Ugandan Population: Implications for Personalized Medicine in an Underrepresented Population.
Samarasinghe SR et al.
Clinical Pharmacology and Therapeutics, 2024
Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum.
Eniayewu O et al.
Clinical Pharmacology and Therapeutics, 2024
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy.
Robinson KM et al.
Clinical Pharmacology and Therapeutics, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.
Kharasch ED et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African Populations.
Twesigomwe D et al.
Clinical Pharmacology and Therapeutics, 2024
Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens.
Wu K et al.
Pharmacogenetics and Genomics, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Genetic polymorphisms of CYP2B6 is a risk of metabolic associated fatty liver disease in Chinese population.
Zhang J et al.
Toxicology and Applied Pharmacology, 2023
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Agyemang N et al.
Pharmacogenetics and Genomics, 2023
Towards Evidence-Based Implementation of Pharmacogenomics in Southern Africa: Comorbidities and Polypharmacy Profiles across Diseases.
Soko ND et al.
Journal of Personalized Medicine, 2023
Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants.
Pan X et al.
Clinical Pharmacology and Therapeutics, 2023
Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia.
Chala A et al.
Cpt: Pharmacometrics & Systems Pharmacology, 2023
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR et al.
International Journal of Molecular Sciences, 2023
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.
Wang PF et al.
British Journal of Clinical Pharmacology, 2022
Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort.
Ximenez JP et al.
British Journal of Clinical Pharmacology, 2022
Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
van Rensburg R et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2022
Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers.
Gufford BT et al.
The Journal of Pharmacology and Experimental Therapeutics, 2022
Trough plasma nevirapine levels, immunologic and virologic responses in composite CYP2B6*6/*18 HIV-infected adult Nigerian patients.
Abdullahi ST et al.
Basic & Clinical Pharmacology & Toxicology, 2022
Newly identified tree shrew cytochrome P450 2B6 (CYP2B6) and pig CYP2B6b are functional drug-metabolising enzymes.
Uno Y et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems, 2022
Does sex alter the relationship between CYP2B6 variation, hydroxybupropion concentration and bupropion-aided smoking cessation in African Americans? A moderated mediation analysis.
Chenoweth MJ et al.
Addiction (abingdon, England), 2022
The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
Maseng MJ et al.
Medicine, 2022
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.
Haas DW et al.
Pharmacogenetics and Genomics, 2022
The Cyp2b6 Gene Polymorphism and Phenotypic Correlation of Efavirenz-Based Combination Therapy Among the Niger Delta Ethnic Population: Implications in Modern Pharmacogenomics.
Bunu SJ et al.
Pharmacogenomics and Personalized Medicine, 2022
Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.
Ngayo MO et al.
Plos One, 2022
Clinical Importance of Potential Genetic Determinants Affecting Propofol Pharmacokinetics and Pharmacodynamics.
Budic I et al.
Frontiers in Medicine, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
Griesel R et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2021
Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.
Leonard MA et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 2021
Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria.
Nwogu JN et al.
Aids (london, England), 2021
Global spectrum of population-specific common missense variation in cytochrome P450 pharmacogenes.
Chong CS et al.
Human Mutation, 2021
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Precision Medicine into Clinical Practice: A Web-Based Tool Enables Real-Time Pharmacogenetic Assessment of Tailored Treatments in Psychiatric Disorders.
Zampatti S et al.
Journal of Personalized Medicine, 2021